文献速递免疫规划传染病防控与疫情报告

间隔8年异源初免-加强H7N7-H7N9流感疫苗的安全性与免疫原性

Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.
PubMed 文献 · Vaccine · 2019-04-04

本研究评估8年前接种两剂IIV1 A/H7N7者,再接种1剂45 mcg IIV1 A/H7N9加强后的免疫原性。初免组加强后第9天和第29天抗体滴度≥40的比例分别为65%和41%,未初免组为10%和0%;AS03佐剂组抗体滴度总体更高。

要点

  • 8年前IIV1 A/H7N7初免者,单剂无佐剂IIV1 A/H7N9加强可产生血清学应答。
  • 加强后第9天和第29天抗体滴度≥40比例初免组为65%和41%,未初免组为10%和0%。
  • AS03佐剂IIV1 A/H7N9受者抗体滴度高于初免-加强组,但2株高致病性毒株例外。

核心结论

  • IIV1 A/H7初免后,即使初免后无抗体应答,延迟8年以1剂无佐剂IIV1 A/H7N9加强仍可诱导血清学应答。
  • 优化初免-加强策略有益于大流行准备。

研究设计与样本

  • 研究向17名既往接种2剂IIV1 A/H7N7者和10名A/H7未暴露者接种1剂含45 mcg IIV1 A/H7N9血凝素的加强针。
  • 用血凝抑制试验检测加强后血清针对同源A/H7N9的抗体,并与储存的AS03佐剂IIV1 A/H7N9受者血清针对9株A/H7N9病毒的抗体滴度比较。
  • ClinicalTrials.gov注册号NCT02586792。

主要发现

  • 加强后第9天和第29天抗体滴度≥40的比例,初免组分别为65%和41%,未初免组分别为10%和0%。
  • AS03佐剂IIV1 A/H7N9受者抗体滴度高于初免-加强组针对一组A/H7N9病毒,但2株高致病性毒株例外。

临床怎么用

  • 大流行准备中可考虑异源初免-加强策略,以单剂加强诱导应答。
  • 需进一步优化初免-加强方案以提升免疫原性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Influenza A/H7N9 viruses are undergoing antigenic drift since their emergence in 2013, and vaccination strategies are needed for pandemic preparedness. Two doses of adjuvanted monovalent inactivated influenza A/H7N9 vaccine (IIV1 A/H7N9) are needed for optimal serological responses. However, administering 2 doses in a pandemic setting might be challenging. We evaluated the immunogenicity of "boosting" with IIV1 A/H7N9 in subjects "primed" 8 years previously with IIV1 A/H7N7. METHODS: We administered 1 booster dose containing 45 mcg of IIV1 A/H7N9 hemagglutinin to 17 recipients of 2 prior doses of IIV1 A/H7N7, and to 10 influenza A/H7-naïve subjects. We tested their post-boosting sera for antibodies (Ab) against homologous influenza A/H7N9 using a hemagglutination inhibition assay; and compared their Ab titers to those in stored sera from recipients of AS03-adjuvanted IIV1 A/H7N9 against 9 strains of influenza A/H7N9 viruses. RESULTS: The percentage of subjects with Ab titers ≥40 on Days 9 and 29 post boosting, respectively, was 65% and 41% in primed subjects and 10% and 0% in unprimed subjects. The Ab titers in recipients of AS03-adjuvanted IIV1 A/H7N9 were higher than those in the prime-boost group against a panel of influenza A/H7N9 viruses, except for 2 highly pathogenic strains. CONCLUSIONS: Priming with IIV1 A/H7 results in serological responses following a delayed boost with 1 dose of unadjuvanted IIV1 A/H7N9, despite lack of antibody response after the prime. Optimizing prime-boost approaches would benefit pandemic preparedness. ClinicalTrials.gov identifier: NCT02586792.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. El Sahly HM, Atmar RL, Patel SM, et al. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019. PMID: 30955980. doi:10.1016/j.vaccine.2019.03.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。